GenEdit Revenue and Competitors

Location

#8478

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • GenEdit's estimated annual revenue is currently $8.8M per year.(i)
  • GenEdit's estimated revenue per employee is $155,000

Employee Data

  • GenEdit has 57 Employees.(i)
  • GenEdit grew their employee count by 2% last year.

GenEdit's People

NameTitleEmail/Phone
1
CSOReveal Email/Phone
2
CEO & Co-founderReveal Email/Phone
3
SVP Business Operations & Co-founderReveal Email/Phone
4
VP, Business DevelopmentReveal Email/Phone
5
VP, Therapeutic Product and Process DevelopmentReveal Email/Phone
6
Associate DirectorReveal Email/Phone
7
Senior Director Corporate StrategyReveal Email/Phone
8
Chief Technology OfficerReveal Email/Phone
9
Chief Scientific OfficerReveal Email/Phone
10
Director, Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M3N/AN/AN/A
#2
$636.2M3178-4%$1BN/A
#3
$24.1M1514%N/AN/A
#4
$0.6M8N/AN/AN/A
Add Company

What Is GenEdit?

GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients. CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. It is easier to use, faster, and more accurate than previous gene editing techniques and thus has the potential for a wide range of therapeutic applications. In particular, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. However, current CRISPR delivery methods rely on viruses and are problematic due to viral-induced toxicity and prolonged Cas9 exposure, increasing off-target effects. A non-viral CRISPR/Cas9 delivery method is needed. In addition, low efficiency levels achieved make it impossible to target certain diseases. GenEdit's novel CRISPR delivery technology has the potential to be a platform delivery system for a broad range of genetic diseases. We also work on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.

keywords:N/A

N/A

Total Funding

57

Number of Employees

$8.8M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.6M57-10%N/A
#2
$4.6M59-11%$237.8M
#3
$7.7M59-3%N/A
#4
$16.5M60-2%N/A
#5
$7.8M60N/AN/A